%0 Journal Article %T Supervivencia de pacientes con c¨¢ncer de pulm¨®n de c¨¦lula no peque£¿a en cuatro instituciones de Colombia %A Cardona %A Andr¨¦s Felipe %A Carranza %A Hern¨¢n %A Vargas %A Carlos Alberto %A Otero %A Jorge Miguel %A Reveiz %A Ludovic %A Reguart %A Noem¨ª %A Carrasco %A Esther %A Ospina %A Edgar %A S¨¢nchez %A Oswaldo %A Ospina %A Vanessa %A Cabrera %A ¨¢ngela Viviana %A Ram¨ªrez %A Diana Carolina %A P¨¦rez %A Juan Carlos %A Torres %A Liliana Patricia %A V¨¦lez %A Carolina %A Serrano %A Silvia Juliana %A Castro %A Carlos %J Revista Venezolana de Oncolog¨ªa %D 2010 %I Scientific Electronic Library Online %X objective: describing results of treatment in patients suffering advanced no small cell according to routine clinical practice. the 70 % of patients suffering debut with advanced disease are determining less than 13 % overall survival in 5 years. methods: 176 patients treated in bogot¨¢. results: the mean age was 64 years; 64 % were male 51 % had ¡Ü1 ecog. the 90 % had metastasis, mainly in the lung and in central nervous system. 76 % received combined therapy as the first line of intervention; 126 subjects were treated with a platinum compounds (cisplatin 38/21.6 % carboplatin 88/50 %) plus some third generation agent or etoposide. thirty-four received monotherapy and eight erlotinib; 3.7 ¡À 1.7 cycles per patient were supplied on average, overall response rate was 29 %, clinical benefit 39 % and the median time to progression was 3.4 months. only the third part of the population received a second line intervention; in this group overall response was 15.8 %, clinical benefit 33.8 % and free time progression was 3.1 months. when follow-up finished, 69.3 % had died, median the overall survival was 9.2 months 26 % of the subjects lived for up to one year. some variables such gender, functional state, history of smoking, administering second line agent and a diagnosis of adenocarcinoma influenced in superlife. conclusions: clinical behaviour and outcomes treatment of patients included in this study were similar to those previously reported in the medical literature. %K cancer %K lung %K non-small cell %K chemotherapy %K overall survival %K progression free survival %K toxicity. %U http://www.scielo.org.ve/scielo.php?script=sci_abstract&pid=S0798-05822010000100010&lng=en&nrm=iso&tlng=en